GO
Loading...

Medicine

More

  • Merck, Iowa firm sign Ebola vaccine licensing deal Monday, 24 Nov 2014 | 1:28 PM ET

    TRENTON, N.J.— Merck& Co., a top creator and seller of vaccines, has joined the fight against Ebola, the often-fatal hemorrhagic virus that's been ravaging parts of West Africa for months. The exclusive deal involves rVSV-EBOV, a vaccine candidate under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of...

  • Nov 24- BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million, betting on a drug that has potential to become the first approved treatment for a rare muscle disorder. "Though the asset has risk given the clinical history, we believe the payoff for BioMarin could be substantial given the unmet need...

  • FDA strengthens warning on device linked to cancer Monday, 24 Nov 2014 | 11:34 AM ET

    The Food and Drug Administration updated its April safety warning, saying doctors should not use the devices, called laparoscopic power morcellators, for performing a hysterectomy or removing uterine fibroids "in the vast majority of women." Maisel said the FDA is recommending that makers of laparoscopic power morcellators immediately include in the...

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • UPDATE 1-BioMarin to buy Prosensa in $840 mln deal Monday, 24 Nov 2014 | 7:39 AM ET

    Nov 24- BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million including milestone payments, aiming to add to its portfolio of drugs to treat rare diseases. BioMarin will offer $17.75 for every Prosensa share and make two milestone payments of $80 million each following U.S. and European approvals for...

  • Family gets $6.75 million in Botox treatment case Thursday, 20 Nov 2014 | 3:41 PM ET

    The verdict, in U.S. District Court in Burlington, came three days after the announcement that Parsippany, New Jersey- based drugmaker Actavis would acquire Botox maker Allergan for $66 billion, one of the biggest acquisitions announced this year. Thursday's verdict came four years after Irvine, California- based Allergan agreed to pay $600 million, pleading...

  • HIV drugs show promise in treating common eye disease Thursday, 20 Nov 2014 | 2:00 PM ET

    WASHINGTON, Nov 20- A class of drugs used for three decades by people infected with the virus that causes AIDS may be effective in treating a leading cause of blindness among the elderly. University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, who led the study published in the journal Science, said macular generation affects an estimated 50 million...

  • US approves new, hard-to-abuse hydrocodone pill Thursday, 20 Nov 2014 | 1:16 PM ET

    The FDA said the medication is difficult to crush, break or dissolve. Purdue Pharma's new drug poses a direct commercial challenge to Zogenix's much-debated drug Zohydro, a twice-a-day hydrocodone tablet approved by the FDA last year. The FDA has been under intense public pressure to combat the national epidemic of prescription opioid abuse.

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Researcher who found cause of Lyme disease dies Thursday, 20 Nov 2014 | 9:52 AM ET

    HAMILTON, Mont.— The Swiss-born researcher who gained international recognition for discovering the bacteria that causes Lyme disease has died in western Montana. A spokesman at the Daly-Leach Chapel said Wilhelm "Willy" Burgdorfer died from complications of Parkinson's disease Monday in Hamilton. He went to the Rocky Mountain Laboratory in Hamilton as a...

  • Report: Global obesity costs hits $2 trillion Thursday, 20 Nov 2014 | 5:45 AM ET

    LONDON— The global cost of obesity has risen to $2 trillion annually— nearly as much as smoking or the combined impact of armed violence, war and terrorism, according to a new report released Thursday. The McKinsey Global Institute consulting firm's report focused on the economics of obesity, putting it among the top three social programs generated by human...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • Early statin use may give long-term heart benefits Wednesday, 19 Nov 2014 | 2:49 PM ET

    CHICAGO— Taking a cholesterol-lowering drug for five years in middle age can lower heart and death risks for decades afterward, and the benefits seem to grow over time, a landmark study of men in Scotland finds. Chris Packard of the University of Glasgow in Scotland. The long-term results were discussed at an American Heart Association conference that ends...

  • Gift of sight     Wednesday, 19 Nov 2014 | 1:41 PM ET

    Second Sight's main product "The Argus II" has been helping people who are blind see again. Second Sight patient Fran Fulton, and Second Sight CEO Dr. Robert Greenberg, discuss the technology.

  • NTSB recommends better sleep disorder screening Wednesday, 19 Nov 2014 | 9:31 AM ET

    NEW YORK— Federal regulators who concluded that an engineer's sleep apnea caused a deadly train derailment in New York adopted several recommendations Wednesday for better screening of such disorders, including a call for improved physician training. The National Transportation Safety Board, meeting in Washington, approved all the conclusions and...

  • Nov 19- Synergy Pharmaceuticals Inc said its experimental drug for opioid-induced constipation was found safe and effective in a mid-stage trial. Synergy Pharmaceuticals shares were up 8 percent in premarket trading. The drug SP-333 showed statistically significant improvement in spontaneous bowel movement in the fourth week of treatment, compared...

  • Nov 19- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash. Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate...

  • Study will test survivors' blood to treat Ebola Tuesday, 18 Nov 2014 | 10:02 PM ET

    The Bill& Melinda Gates Foundation is giving $5.7 million to scale up production of the treatments for the project in Guinea and other Ebola-affected countries in Africa. Besides helping Ebola patients now, plasma "could be a tool for a future epidemic as well" from different viruses, Microsoft co-founder Bill Gates said in an interview with The Associated...

  • Trading 3-D: Pro loves HPQ     Tuesday, 18 Nov 2014 | 5:17 PM ET

    The "Fast Money" traders dig into the play on 3-D printing companies Hewlett-Packard and Organovo.